Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate…
Pharmaceuticals, Biotechnology and Life Sciences
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate…
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing…
Figure 1. ELF Score — Change from Baseline at Week 12 Bexotegrast (PLN-74809) at 320 mg was well tolerated over…
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid)…
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results…
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 01, 2024…
– Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD…
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER…
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…